ARTICLE | Clinical News
Autologous T cell therapy against CD19: Completed Phase I/II enrollment
August 8, 2016 7:00 AM UTC
Kite completed enrollment of 72 patients with refractory diffuse large B cell lymphoma (DLBCL) in the Phase II portion of the open-label, U.S. Phase I/II ZUMA-1 trial evaluating a single IV infusion o...